Literature DB >> 29095531

Low-level red LED light inhibits hyperkeratinization and inflammation induced by unsaturated fatty acid in an in vitro model mimicking acne.

Wen-Hwa Li1, Ali Fassih1, Curt Binner1, Ramine Parsa1, Michael D Southall1.   

Abstract

BACKGROUND AND
OBJECTIVE: Acne vulgaris is a chronic inflammatory disease of the pilosebaceous units (PSU), associated with increased sebum production, abnormal follicular keratinization (hyperkeratinization), follicular overgrowth of Propionibacterium acnes (P. acnes), and increased inflammatory mediator release. Light therapy has attracted medical interests as a safe alternative treatment for acne. Both blue and red light therapies at high doses >10 J/cm2 have demonstrated marked effects on inflammatory acne lesions. However, few studies have investigated the effects of lower doses of light. The aim of this study is to investigate the biological effects of lower doses of red light at 0.2-1.2 J/cm2 for acne using an in vitro model previously developed to mimic the inflammation and hyperkeratinization observed clinically in acne.
MATERIALS AND METHODS: Human epidermal equivalents were topically exposed to an unsaturated fatty acid, oleic acid (OA), followed by red light-emitting diode (LED) light treatments (light-plus-OA treatments). Endpoints evaluated included the proinflammatory cytokine IL-1α, epidermal barrier integrity, as measured by transepithelial electrical resistance (TEER), and stratum corneum (SC) thickness to monitor hyperkeratinization.
RESULTS: OA-induced IL-1α release was significantly (P < 0.05) reduced following red LED light at 0.2, 0.5, and 1.2 J/cm2 , from 266 ± 11 pg/ml of no-light-plus-OA-treated (OA treatment without light) controls to 216 ± 9, 231 ± 8, and 212 ± 7 pg/ml, respectively. Histological examination showed that SC thickening following OA treatment was reduced from 43% of total epidermis for no-light-plus-OA treatment to 37% and 38% of total epidermis following 0.5 and 1.1 J/cm2 red light plus OA treatment, respectively (P < 0.05). Moreover, 1.1 J/cm2 red-light-plus-OA treatment improved OA-induced TEER changes from 29% of baseline for no-light-plus-OA treatment, to 36% of baseline.
CONCLUSION: Low level red LED light therapy could provide beneficial effects of anti-inflammation, normalizing pilosebaceous hyperkeratinization, and improving barrier impairment in Acne vulgaris. Lasers Surg. Med. 50:158-165, 2018.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  acne photobiomodulation therapy; barrier; hyperkeratinization; inflammation; oleic acid; red light-emitting diode (LED) light

Mesh:

Substances:

Year:  2017        PMID: 29095531     DOI: 10.1002/lsm.22747

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  5 in total

1.  Photobiomodulation with a wavelength > 800 nm induces morphological changes in stem cells within otic organoids and scala media of the cochlea.

Authors:  So-Young Chang; Min Young Lee
Journal:  Lasers Med Sci       Date:  2021-02-18       Impact factor: 3.161

Review 2.  Effectiveness of photopneumatic technology: a descriptive review of the literature.

Authors:  Ali Rajabi-Estarabadi; Siri Choragudi; Isabella Camacho; Kevin J Moore; Jonette E Keri; Keyvan Nouri
Journal:  Lasers Med Sci       Date:  2018-08-24       Impact factor: 3.161

3.  The Anti-Acne Effect of Near-Infrared Low-Level Laser Therapy.

Authors:  Anna Szymańska; Elzbieta Budzisz; Anna Erkiert-Polguj
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-08-25

4.  The immunomodulatory potential of phage therapy to treat acne: a review on bacterial lysis and immunomodulation.

Authors:  Juan Farfán; John M Gonzalez; Martha Vives
Journal:  PeerJ       Date:  2022-07-25       Impact factor: 3.061

5.  The Effect of Low-Level Light Therapy on Capsaicin-Induced Peripheral and Central Sensitization in Healthy Volunteers: A Double-Blinded, Randomized, Sham-Controlled Trial.

Authors:  Kordula Lang-Illievich; Raimund Winter; Gudrun Rumpold-Seitlinger; Kurt Schicho; Christian Dorn; Christoph Klivinyi; Helmar Bornemann-Cimenti
Journal:  Pain Ther       Date:  2020-10-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.